Compare Amphastar Pharmaceuticals Inc (AMPH) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Crown Castle International Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Crown Castle International Corp trades at $73.76 (market cap $31.32B). The key difference: Crown Castle International Corp is far larger — about 36.3× Amphastar Pharmaceuticals Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CCI | |
|---|---|---|
Market Cap | $863.95M | $31.32B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $103.79 |
52-Week Low | $16.87 | $73.61 |
Enterprise Value | $1.26B | $53.68B |
Dividend Yield | — | 5.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Crown Castle (CCI) trades at $75.59, up 0.89% on the day, but technical indicators signal a bearish trend with the stock near recent lows. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, while revenue has declined from $7.0B in 2023 to $4.26B in 2025. Analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting potential upside. Recent news highlights strategic shifts, including the sale of its fiber business and a focus on U.S. tower operations.
The outlook for CCI hinges on execution of its pure-play tower strategy amid high debt levels and competitive pressures. Investment appeal lies in its 5.5% dividend yield and discounted valuation, but risks include declining revenue, negative shareholder equity, and sensitivity to interest rates. Wall Street sees value if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
